SILVER SPRING, Md., June 25, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Fintepla (fenfluramine), a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in patients age 2 and older. Dravet syndrome is a...
from PR Newswire: https://ift.tt/2VgB9eD
No comments:
Post a Comment